Quick Answer
Sonoma Pharmaceuticals, Inc. reported Net Income Loss of -$3.46 million for the year ending 2025.
- Sonoma Pharmaceuticals, Inc. showed an increase of +28.5% in Net Income Loss from 2024 to 2025.
- This data is from Sonoma Pharmaceuticals, Inc.'s annual report (Form 10-K), filed with the SEC on June 17, 2025.
- XBRL data for this metric is available from 2011 to 2025 (15 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2013: -$1.40 million | Q4 2013: -$611.0 thousand | Q2 2014: -$70.0 thousand | Q3 2014: -$718.0 thousand | Q4 2014: -$5.91 million | Q2 2015: -$2.34 million | Q3 2015: -$1.76 million | Q4 2015: -$3.15 million | Q2 2016: -$2.57 million | Q3 2016: -$1.95 million | Q4 2016: $16.23 million | Q2 2017: -$3.51 million | Q3 2017: -$2.87 million | Q4 2017: -$3.19 million | Q2 2018: -$3.46 million | Q3 2018: -$2.82 million | Q4 2018: -$2.30 million | Q2 2019: $715.0 thousand | Q3 2019: -$1.20 million | Q4 2019: -$1.08 million | Q2 2020: $240.0 thousand | Q3 2020: $120.0 thousand | Q4 2020: -$650.0 thousand | Q2 2021: -$1.10 million | Q3 2021: -$100.0 thousand | Q4 2021: -$944.0 thousand | Q2 2022: -$887.0 thousand | Q3 2022: -$1.02 million | Q4 2022: -$1.94 million | Q2 2023: -$1.42 million | Q3 2023: -$1.48 million | Q4 2023: -$866.0 thousand | Q2 2024: -$1.14 million | Q3 2024: -$610.0 thousand | Q4 2024: -$928.0 thousand | Q2 2025: -$1.24 million | Q3 2025: -$534.0 thousand | Q4 2025: -$819.0 thousand.
- Over the full 15 years of available data (2011 to 2025), Sonoma Pharmaceuticals, Inc.'s Net Income Loss has grown by 56.5%.
- Historical annual values: Fiscal year 2025: -$3.46 million | Fiscal year 2024: -$4.84 million | Fiscal year 2023: -$5.15 million | Fiscal year 2022: -$5.09 million | Fiscal year 2021: -$3.95 million | Fiscal year 2020: -$3.31 million | Fiscal year 2019: -$11.80 million | Fiscal year 2018: -$14.33 million | Fiscal year 2017: $9.27 million | Fiscal year 2016: -$10.16 million | Fiscal year 2015: -$8.20 million | Fiscal year 2014: $3.74 million | Fiscal year 2013: -$5.43 million | Fiscal year 2012: -$7.33 million | Fiscal year 2011: -$7.95 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: